Pulmoner arter basıncının serum seruloplazmin düzeyi ile ilişkisi Türkçe

Öz

Amaç: Pulmoner arter basıncı yüksekliği PAB etiyolojisinde pek çok faktörün olduğu kompleks bir hastalıktır. Demir metabolizmasında, bakır taşınmasında görevleri olan, aynı zamanda antioksidan ve akut faz reaktanı bir enzim olan seruloplazminin Cp pulmoner arteryel hipertansiyon PAH hastalarında düzeyleri bilinmemektedir. Bu çalışma PAB ile serum Cp düzeyinin ilişkisini araştırmak üzere planlandı.Materyal ve metod: Çalışmaya kardiyoloji ekokardiyografi laboratuarına başvuran ve PAB ölçülen 100 ardışık olgu alındı. Altta yatan nedene bakılmaksızın sistolik PAB 40 mm Hg ve üstündeki 50 hasta ise PAH grubu olarak; 40 mmHg altında olan 50 hasta kontrol grubu olarak ayrıldı. Tüm olgularda serum Cp düzeyi spektrofotometrik olarak bakıldı. Bulgular: PAH grubunda serum Cp düzeyi kontrollere göre yüksekti 668,1±107,4 μg/dL'e karşılık 623,3±101,1 μg/dL; p=0,012 . Pearson korelâsyon analizinde serum Cp düzeyi ile PAB, açlık kan şekeri ve hemoglobin düzeyi arasındaki ilişki anlamlı iken p=0,003 lineer regresyon analizinde bağımsız ilişki izlenmedi p=0,068 . Sonuç: PAH'da serum Cp artışı, bu enzimin akut faz reaktanı, hipoksi tarafından indüklenebilir bir enzim olması, PAH sırasında artan bazı oksidanlar tarafından oksidatif modifikasyona uğrayarak oksidan gibi davranması ile ilişkili olabileceğini düşündürmektedir

Anahtar Kelimeler

• Pulmoner hipertansiyon,seruloplazmin

The relationship between pulmonary artery pressure and ceruloplasmin levels

Öz

Background: Increased pulmonary artery pressure PAP is a complex disease and unknown etiology. Ceruloplasmin Cp is a plasma protein associated with iron metabolism and copper transport, an antioxidant and an acute phase reactant. Cp levels are not known in pulmonary arterial hypertension PAH . This study was designed to investigate the relationship between PAP and serum Cp levels.Methods: One hundred consecutive patients, who admitted to cardiology echocardiography laboratory and PAP pressure can be measured, were included in this study. Regardless of the underlying cause, PAH group 50 patient with systolic PAP 40 mm Hg and above, and control group 50 patient with PAP less than 40 mmHg. In all cases, serum Cp levels were determined spectrophotometrically.Results: Serum Cp levels 668.1 ± 107.4 μg/dL vs. 623.3 ± 101.1 μg/dL, p = 0.012 were higher in PAH group than in controls. Pearson's correlation analysis showed a significant relationship among serum Cp levels, fasting blood glucose and hemoglobin level p=0,003 . With linear regression analysis, only independent relationship among serum Cp, the level of fasting blood glucose and hemoglobin p = 0.068 .Conclusions: Increased Cp in patient PAH might be related to features of acute phase reactant of this enzyme, inducible by hypoxia, act as oxidant with undergoes oxidative modification by some increased oxidants in PAH

Anahtar Kelimeler

• Pulmonary hypertension,ceruloplasmin

Kaynakça

1. ) Newman JH, Fanburg BL, Archer SL, et al. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 2004; 109: 2947-52.
2. ) Healy J, Tipton K. Ceruloplasmin and what it might do. J Neural Transm 2007; 114: 777-81.
3. ) Bogaard HJ, Mizuno S, Guignabert C, et al. Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. Am J Respir Cell Mol Biol 2012; 46: 582
4. ) Erel O. Automated measurement of serum ferroxidase activity. Clin Chem 1998; 44:2313-9.
5. ) Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Biochem 2004; 37: 112-9.
6. ) Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
7. ) IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard comprehensive and minimal care. Diabet Med 2006; 23: 579-93.
8. ) Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 201; 32: 1769-818.

9. ) Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989; 2: 358-67.
10. ) Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Resp Crit Care Med 2009; 179: 615–21.
11. ) Erol Ç, Özkan M. Kli nik ekokardiyografi ve diğer görüntüleme yöntemleri. İkinci baskı MN Medikal & Nobel basım evi, 2008.
12. ) Holmberg CG, Laurell C-B. Investigations in serum copper. II. Isolation of the Copper containing protein, and a description of its properties. Acta Chem Scand. 1948; 2: 550-6.
13. ) Brunetti ND, Pellegrino PL, Correale M, De Gennaro L, Cuculo A, Di Biase M. Acute phase proteins and systolic dysfunction in subjects with a c u t e m y o c a r d i a l i n f a r c t i o n . J T h r o m b Thrombolysis 2008; 26: 196-202.
14. ) Kwon YS, Chi SY, Shin HJ, et al. Plasma C- reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci 2010; : 1487-91.
15. ) Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994; : 929-33.
16. ) Masri FA, Comhair SA, Dostanic-Larson I, et al. Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension. Clin Transl Sci ; 1: 99-106. ) Redout EM, van der Toorn A, Zuidwijk MJ, et al. Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. Am J Physiol Heart Circ Physiol 2010; 298: 1038-47.
17. ) Wong CM, Bansal G, Pavlickova L, Marcocci L, Suzuki YJ. Reactive Oxygen Species and Antioxidants in Pulmonary Hypertension. Antioxid R e d o x S i g n a l 2 0 1 2 ; 1 1 . doi:10.1089/ars.2012.4568.
18. ) Kang JH, Kim KS, Choi SY, Kwon HY, Won MH. Oxidative modification of human ceruloplasmin by peroxyl radicals. Biochim Biophys Acta 2001; 1568: 6.
19. ) Samokyszyn VM, Miller DM, Reif DW, Aust SD. Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin. J Biol Chem 1989; : 21-6.
20. ) Bailey DM, Dehnert C, Luks AM, et al. High- altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailability. J Physiol 2010; 588: 47.
21. ) Martin F, Linden T, Katschinski DM, et al. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood. 2005; 105: 4613-9.
22. ) Mukherjee D. Atherogenic vascular stiffness and hypertension: cause or effect? JAMA 2012; 308: 919
23. ) Lee MJ, Jung CH, Hwang JY, et al. Association Between Serum Ceruloplasmin Levels and Arterial Stiffness in Korean Men with Type 2 Diabetes Mellitus. Diabetes Technol Ther 2012; 14:1091-7
24. ) Smith TG, Talbot NP, Privat C, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA 2009; 302: 1444-50.
25. Ruiter G, Lankhorst S, Boonstra A, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 2011; 37: 1386-91.
26. Decker I, Ghosh S, Comhair SA, et al. High levels of zinc-protoporphyrin identify iron metabolic abnormalities in pulmonary arterial hypertension. Clin Transl Sci 2011; 4: 253-8.
27. Zhao QH, Peng FH, Wei H, et al. Serum high- density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol 2012; 110: 433-9.
28. Zamanian RT, Hansmann G, Snook S, et al. I n s u l i n r e s i s t a n c e i n p u l m o n a r y a r t e r i a l hypertension.Eur Respir J 2009; 33: 318-24.